Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Broadly neutralizing antibodies targeting new sites of vulnerability in hepatitis C virus E1E2.

Colbert MD, Flyak AI, Ogega CO, Kinchen VJ, Massaccesi G, Hernandez M, Davidson E, Doranz BJ, Cox AL, Crowe JE Jr, Bailey JR.

J Virol. 2019 May 8. pii: JVI.02070-18. doi: 10.1128/JVI.02070-18. [Epub ahead of print]

PMID:
31068427
2.

Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.

Williamson LE, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz BJ, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE Jr.

J Virol. 2019 Apr 3;93(8). pii: e01439-18. doi: 10.1128/JVI.01439-18. Print 2019 Apr 15.

PMID:
30728263
3.

Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.

Kinchen VJ, Zahid MN, Flyak AI, Soliman MG, Learn GH, Wang S, Davidson E, Doranz BJ, Ray SC, Cox AL, Crowe JE Jr, Bjorkman PJ, Shaw GM, Bailey JR.

Cell Host Microbe. 2018 Nov 14;24(5):717-730.e5. doi: 10.1016/j.chom.2018.10.012.

PMID:
30439341
4.

HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.

Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE Jr, Bailey JR, Bjorkman PJ.

Cell Host Microbe. 2018 Nov 14;24(5):703-716.e3. doi: 10.1016/j.chom.2018.10.009.

PMID:
30439340
5.

Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap.

Ilinykh PA, Santos RI, Gunn BM, Kuzmina NA, Shen X, Huang K, Gilchuk P, Flyak AI, Younan P, Alter G, Crowe JE Jr, Bukreyev A.

PLoS Pathog. 2018 Aug 23;14(8):e1007204. doi: 10.1371/journal.ppat.1007204. eCollection 2018 Aug.

6.

Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.

Kuzmina NA, Younan P, Gilchuk P, Santos RI, Flyak AI, Ilinykh PA, Huang K, Lubaki NM, Ramanathan P, Crowe JE Jr, Bukreyev A.

Cell Rep. 2018 Aug 14;24(7):1802-1815.e5. doi: 10.1016/j.celrep.2018.07.035.

7.

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.

Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, Turner HL, Fusco ML, Bramble MS, Hoff NA, Binshtein E, Kose N, Flyak AI, Flinko R, Orlandi C, Carnahan R, Parrish EH, Sevy AM, Bombardi RG, Singh PK, Mukadi P, Muyembe-Tamfum JJ, Ohi MD, Saphire EO, Lewis GK, Alter G, Ward AB, Rimoin AW, Bukreyev A, Crowe JE Jr.

Immunity. 2018 Aug 21;49(2):363-374.e10. doi: 10.1016/j.immuni.2018.06.018. Epub 2018 Jul 17.

8.

Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates.

Gilchuk P, Mire CE, Geisbert JB, Agans KN, Deer DJ, Cross RW, Slaughter JC, Flyak AI, Mani J, Pauly MH, Velasco J, Whaley KJ, Zeitlin L, Geisbert TW, Crowe JE Jr.

J Infect Dis. 2018 Nov 22;218(suppl_5):S565-S573. doi: 10.1093/infdis/jiy295.

PMID:
29982718
9.

Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.

Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, Gulka CP, Ilinykh PA, Shen X, Huang K, Ramanathan P, Turner H, Fusco ML, Lampley R, Kose N, King H, Sapparapu G, Doranz BJ, Ksiazek TG, Wright DW, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr.

Nat Microbiol. 2018 Jun;3(6):670-677. doi: 10.1038/s41564-018-0157-z. Epub 2018 May 7.

10.

The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding.

King LB, Fusco ML, Flyak AI, Ilinykh PA, Huang K, Gunn B, Kirchdoerfer RN, Hastie KM, Sangha AK, Meiler J, Alter G, Bukreyev A, Crowe JE Jr, Saphire EO.

Cell Host Microbe. 2018 Jan 10;23(1):101-109.e4. doi: 10.1016/j.chom.2017.12.003.

11.

Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.

Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE Jr, Bailey JR.

Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):E82-E91. doi: 10.1073/pnas.1718441115. Epub 2017 Dec 18.

12.

Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance.

Bailey JR, Flyak AI, Cohen VJ, Li H, Wasilewski LN, Snider AE, Wang S, Learn GH, Kose N, Loerinc L, Lampley R, Cox AL, Pfaff JM, Doranz BJ, Shaw GM, Ray SC, Crowe JE Jr.

JCI Insight. 2017 May 4;2(9). pii: 92872. doi: 10.1172/jci.insight.92872. eCollection 2017 May 4.

13.

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.

Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Crowe JE Jr, Zeitlin L, Geisbert TW.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8711. doi: 10.1126/scitranslmed.aai8711.

14.

A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses.

Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE Jr, Aman MJ, Dye JM, Lai JR, Chandran K.

Science. 2016 Oct 21;354(6310):350-354. Epub 2016 Sep 8.

15.

Structures of Ebola virus GP and sGP in complex with therapeutic antibodies.

Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE Jr, Andersen KG, Saphire EO, Ward AB.

Nat Microbiol. 2016 Aug 8;1(9):16128. doi: 10.1038/nmicrobiol.2016.128.

16.

Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies.

Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE Jr, Chandran K, Saphire EO.

MBio. 2016 Feb 23;7(1):e02154-15. doi: 10.1128/mBio.02154-15.

17.

Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies.

Ilinykh PA, Shen X, Flyak AI, Kuzmina N, Ksiazek TG, Crowe JE Jr, Bukreyev A.

J Virol. 2016 Mar 28;90(8):3890-3901. doi: 10.1128/JVI.00101-16. Print 2016 Apr.

18.

Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.

Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr.

Cell. 2016 Jan 28;164(3):392-405. doi: 10.1016/j.cell.2015.12.022. Epub 2016 Jan 21.

19.

Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE Jr.

Cell Host Microbe. 2015 Jul 8;18(1):86-95. doi: 10.1016/j.chom.2015.06.009. Erratum in: Cell Host Microbe. 2015 Sep 9;18(3):382. Khomadiak, Solomiia [corrected to Khomandiak, Solomiia].

20.

Structural basis for Marburg virus neutralization by a cross-reactive human antibody.

Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, Hammel M, Crowe JE Jr, Saphire EO.

Cell. 2015 Feb 26;160(5):904-912. doi: 10.1016/j.cell.2015.01.041.

21.

Mechanism of human antibody-mediated neutralization of Marburg virus.

Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Ward AB, Saphire EO, Bukreyev A, Crowe JE Jr.

Cell. 2015 Feb 26;160(5):893-903. doi: 10.1016/j.cell.2015.01.031.

22.

IL-15 regulates homeostasis and terminal maturation of NKT cells.

Gordy LE, Bezbradica JS, Flyak AI, Spencer CT, Dunkle A, Sun J, Stanic AK, Boothby MR, He YW, Zhao Z, Van Kaer L, Joyce S.

J Immunol. 2011 Dec 15;187(12):6335-45. doi: 10.4049/jimmunol.1003965. Epub 2011 Nov 14.

23.

Supplemental Content

Loading ...
Support Center